Bruce Carter

Bruce Leonard Andrews Carter is Non-Executive Chairman at Enanta Pharmaceuticals, Inc. since 2015, Chairman at ALSP Orchid Acquisition Corp.
I, Director at Dr. Reddy's Laboratories, Inc., Independent Director at Aurigene Oncology Ltd., Professor at the University of Washington since 1986, and Senior Advisor at Accelerator Services Corp.
Former roles include Chairman at ZymoGenetics, Inc. from 2009 to 2010, Executive Chairman at Global Alliance for TB Drug Development in 2013, Chairman at Xencor, Inc. from 2009 to 2017, Executive Chairman at Immune Design Corp.
from 2009 to 2011, Executive Chairman at Infectious Disease Research Institute in 2011, Chairman at Infectious Disease Research Institute, Independent Director at QLT, Inc. from 2006 to 2012, Independent Non-Executive Director at Dr. Reddy's Laboratories Ltd. from 2008 to 2022, Director at Renovis, Inc. from 2005 to 2008, Independent Director at Mirati Therapeutics, Inc. from 2016 to 2024, Independent Director at Regulus Therapeutics, Inc. from 2012 to 2015, Director at Immune Design Corp.
from 2000 to 2009, Chief Scientific Officer & Executive VP at Novo Nordisk A from 1994 to 1998, and Head-Molecular Genetics at G.D.
Searle & Co., Inc. from 1982 to 1986.
Education includes a doctorate from Queen Elizabeth College and an undergraduate degree from The University of Nottingham.